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Objectives: Tigecycline is a broad-spectrum antibiotic approved for the treatment of complicated intra-abdom-
inal infections (cIAIs). The efficacy of tigecycline when administered as monotherapy or in combination with
other antibacterials in the treatment of cIAIs in routine clinical practice is described.
Patients and methods: Individual patient-level data were pooled from five European observational studies (July
2006 to October 2011).
Results: A total of 785 cIAI patients who received tigecycline were included (mean age 63.1+14.0 years). Of
these, 56.6% were in intensive care units, 65.6% acquired their infection in hospital, 88.1% had at least one
comorbidity and 65.7% had secondary peritonitis. The mean Acute Physiology and Chronic Health Evaluation
(APACHE) II and Sequential Organ Failure Assessment (SOFA) scores at the beginning of treatment were
16.9+7.6 (n¼614) and 7.0+4.2 (n¼108), respectively, indicating high disease severity. Escherichia coli
(41.8%), Enterococcus faecium (40.1%) and Enterococcus faecalis (21.1%) were the most frequently isolated
pathogens; 49.1% of infections were polymicrobial and 17.5% were due to resistant pathogens. Overall,
54.8% (n¼430) received tigecycline as monotherapy and 45.2% (n¼355) as combination therapy for a
mean duration of 10.6 days. Clinical response rates at the end of treatment were 77.4% for all patients
(567/733), 80.6% for patients who received tigecycline as monotherapy (329/408), 75.2% for patients with
a nosocomial infection (354/471), 75.8% for patients with an APACHE II score .15 (250/330) and 54.2%
(32/59) for patients with a SOFA score ≥7.
Conclusions: In these real-life studies, tigecycline, alone and in combination, achieved favourable clinical re-
sponse rates in patients with cIAI with a high severity of illness.
Keywords: broad-spectrum antibacterial therapy, generalized peritonitis, non-interventional studies, glycylcycline antibiotics
Introduction
Complicated intra-abdominal infections (cIAIs) are difficult to
manage, often leading to substantial morbidity and mortality
in affected patients.1 Failure to initiate appropriate antimicrobial
therapy early in the course of treatment can lead to an increased
risk of clinical failure and increased healthcare costs.2 – 4 cIAIs are
commonly defined as infections that extend into the peritoneal
space and are associated with either abscess formation or
peritonitis.5 From a clinical perspective, peritonitis is further cate-
gorized as primary [no loss of gastrointestinal (GI) tract integrity],
secondary (loss of GI tract integrity, usually by perforation or
from infected viscera such as the appendix) and tertiary (recur-
rent infection following a primary or secondary peritonitis).4,6
Secondary peritonitis is the most common form of cIAI and
can be further differentiated into community-acquired (70%
of all secondary peritonitis) and post-operative (30%).6 These
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infections (post-operative and tertiary peritonitis) are usually
polymicrobial and have an increasing likelihood of being due to
antimicrobial-resistant strains.4 Local epidemiology is variable,
but some of the most commonly isolated pathogens in cIAIs
are Gram-negative Enterobacter spp., Escherichia coli, Klebsiella
spp., Proteus spp., Pseudomonas aeruginosa and the Gram-
positive Enterococcus spp., Staphylococcus spp. and Streptococ-
cus spp.4
The epidemiological shift towards drug-resistant pathogens in
cIAIs, together with the limited number of currently available
appropriate antimicrobial agents, presents a challenge for
the successful management of this infection, especially in the
population of severely ill, high-risk patients. Tigecycline is a broad-
spectrum antibiotic with known activity against multiple patho-
gens often isolated in patients with cIAI.7 – 10 The clinical efficacy
and safety of tigecycline monotherapy for the treatment of cIAIs
has been studied in comparison with a standard regimen of imipe-
nem/cilastatin in several Phase III randomized clinical trials
(RCTs),11 – 14 and in comparison with a commonly used combin-
ation of ceftriaxone sodium plus metronidazole in a multicentre,
open-label, randomized study.15 The results of these trials demon-
strated that tigecycline was as efficacious as the comparators for
the treatment of cIAIs with a similar safety profile. In September
2010, the US FDA issued a warning regarding an imbalance in
overall mortality in patients treated with tigecycline that was
noted in the completed clinical trials.16 A number of
meta-analyses have also noted numerically higher all-cause mor-
tality in patients treated with tigecycline versus comparators in
RCTs.17 – 20 The European Medicines Agency (EMA) reviewed the
evidence and concluded that the benefits of tigecycline continue
to outweigh its risks; however, they issued a recommendation
that tigecycline should be used only when it is known or suspected
that other antibiotics are not suitable.21
The RCTs conducted to date and included in the meta-analyses
have included only a small number of intensive care unit (ICU)
patients. In real-life clinical practice, tigecycline may be an
option for the treatment of patients with complicated infections
that are resistant to other available agents.7 Many of these
patients could be critically ill in an ICU or surgical ward, with sub-
stantial comorbidities and higher disease severity than those
treated with tigecycline in the published trials.22 Further data are
needed to clarify the role of tigecycline in the treatment of cIAIs
in these critically ill patients.
The objective of this analysis was to evaluate the clinical effi-
cacy of tigecycline in patients with cIAI treated in the routine
hospital care setting in five non-interventional, observational
studies conducted in four European countries [Germany, Italy,
France and two studies in Spain (Spain-1 and Spain-2)]. The
characteristics and comorbidities of patients with cIAI and the
prescription of tigecycline and concomitant use of other antibio-
tics were also evaluated.
Patients and methods
The analysis included data documented by hospital-based physicians on
the treatment and outcomes of patients receiving tigecycline in five non-
interventional, observational studies conducted in Europe from July 2006
to October 2011. The study from Germany has been published in full23,24
and preliminary data from three of the studies (Italy, France and Spain-2)
have been presented or published previously.25 – 27 The design of each
study and the methodology of data acquisition, assessment of clinical
efficacy and the statistical analysis of the five observational studies is
provided in detail in the accompanying article by Bassetti et al.28
In brief, due to the observational nature of the studies, there were few
protocol specifications or inclusion/exclusion criteria. Hospitalized
patients were included if they received tigecycline for any indication
during the study period. Spain-1 included only patients with a diagnosis
of complicated skin and soft-tissue infection (cSSTI) or cIAI. Two studies
(France and Spain-2) included only patients admitted to the ICU. The ad-
ministration of tigecycline, dosage, duration of treatment and prescrip-
tion of other antibiotics during or after the start of tigecycline were at
the discretion of the physician. All concomitant medications were permit-
ted. The standard approved dosage of tigecycline is an initial loading
dose of 100 mg, followed by 50 mg administered intravenously every
12 h (twice daily), as recommended in the summary of product
characteristics.7
This research was conducted in accordance with the Declaration of
Helsinki and all national and institutional standards. The protocol
of each study was approved by the local ethics committee or institutional
review board. Due to the non-interventional, observational nature of
the studies, written informed consent was not required for enrolment
in the studies in Germany, Italy and Spain-2. Written informed consent
was obtained from patients prior to participation in the studies from
France and Spain-1.
Diagnosis of cIAI
The diagnosis and classification of cIAI was at the discretion of the phys-
ician. cIAIs are commonly defined as complicated when a patient has to
be scheduled for a laparotomy or percutaneous aspiration and meets at
least three of the following five criteria: (i) fever (rectal temperature
38.58C/101.38F); (ii) a white blood cell count of 12000 cells/mm3;
(iii) symptoms referable to the abdominal cavity (e.g. anorexia, nausea,
vomiting and pain); (iv) signs of intra-abdominal infection, e.g. tender-
ness (with or without rebound), involuntary guarding, absence of bowel
sounds, or abdominal wall rigidity; and (v) radiological evidence of GI
perforation or localized collections of potentially infected material.5
cIAIs were classified as localized or generalized peritonitis or
intra-abdominal abscess. cIAIs that had spread beyond the initial local
site were further classified as primary peritonitis (no loss of GI tract integ-
rity), secondary peritonitis (loss of GI tract integrity, usually by perforation
or from infected viscera such as the appendix) or tertiary peritonitis (re-
current infection) as pre-specified in the case report form.4,6
Data acquisition and evaluations
Data were collected on case report forms at the start of therapy with
tigecycline and included patients’ characteristics, infection diagnosis,
disease severity score, microbiological pathogens isolated and therapy
regimens. A description of the cIAI diagnosis was recorded, including
the site of infection and classification of peritonitis as primary, secondary
or tertiary. The severity of disease at the start of tigecycline therapy was
evaluated by the Acute Physiology and Chronic Health Evaluation
(APACHE) II score in Germany, Italy, Spain-1 and Spain-2 and by the
Sequential Organ Failure Assessment (SOFA) score in France and
Spain-2. Reasons for tigecycline use were pre-specified in the case
report form with check boxes. Local hospital laboratory and microbiology
techniques were used to identify isolated pathogens in four studies
(Germany, Spain-1, France and Spain-2).29 The pathogenic species (or
species groups) to be documented were pre-specified in the case report
form with check boxes.
Clinical outcome
Clinical outcome was assessed by the investigator at the end of treat-
ment (EOT) or upon discharge. For this analysis, patients who were
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assessed by the investigator as ‘cured’ or ‘improved, with no further anti-
biotic required’ were assigned an outcome of ‘response’ and patients who
were assessed by the investigator as ‘failure’ or ‘improved, with further
antibiotic required’ were assigned an outcome of ‘non-response’. Patients
whose clinical outcome could not be assessed for any reason were
assigned an outcome of ‘indeterminate’. Patients who died following a
successful response to tigecycline at EOT were counted as ‘responders’
and patients who died before or at EOT were counted as ‘non-responders’.
Safety
The numbers of adverse events (AEs), serious AEs (SAEs), premature dis-
continuations and deaths occurring at any time during the study, includ-
ing the follow-up period, were recorded. Mortality rates were examined
by disease severity score at the time of tigecycline administration. A
detailed description of the criteria for the assessment of safety is pro-
vided in the accompanying paper by Guirao et al.30
Statistical analysis
Descriptive statistics included relative frequencies for categorical vari-
ables and means (and standard deviations) or medians (and IQRs) for
continuous variables. A pooled analysis of patient-level data from the
five studies was conducted for selected characteristics. Only patients
with a single diagnosis of cIAI were included; patients who were diag-
nosed with cIAI plus another infection (e.g. both cIAI and cSSTI) were
excluded. Data were analysed in tabulated summaries with the
number of patients with available (i.e. non-missing) data as the denom-
inator. Clinical response rates were calculated for patients who received
the standard dose of tigecycline as recommended in the summary of
product characteristics7 and were stratified according to mean APACHE
II (≤15 or .15) and SOFA (,7 or ≥7) scores documented at baseline,
mode of infection acquirement (nosocomial or community-acquired)
and treatment with tigecycline as monotherapy or in combination
therapy, and as first-line or second-line therapy.
Results
Patient characteristics
Across the five studies, a total of 785 patients with cIAI were
treated with tigecycline, representing 44.1% of all patients.
Patients’ characteristics at the start of tigecycline therapy, in-
cluding demographics, disease severity scores and comorbidities,
are shown in Table 1. Of the cIAI patients with available data,
58.2% were male, with a mean age of 63.1+14.0 years and a
mean body mass index (BMI) of 27.4+6.7 kg/m2; 49.2% of
patients were over the age of 65 years. The cIAIs were primarily
classified as nosocomial (65.6% overall), although there was a
range across the studies, from 49.5% in Spain-1 to 90.6%
in Spain-2. The majority of patients had a history of prior anti-
bacterial therapy (76.9%) and suffered from at least one co-
morbidity (88.1%). Of 689 patients with one or more
comorbidities, these included hypertension (58.4%), diabetes
mellitus (30.4%), arteriosclerosis/coronary heart disease
(26.9%) and renal insufficiency (24.7%); 22.8% of patients
were classified as obese.
There was heterogeneity between the studies with regard to
the percentage of patients enrolled from the ICU, with all
patients (100.0%) in France and Spain-2 in the ICU at the time
of tigecycline administration, compared with 1.1% of patients
in Spain-1, 46.3% in Italy and 61.7% in Germany (Table 1).
Disease severity scores
APACHE II scores were collected at baseline in four of the five
studies and were documented in a total of 614 patients in
Germany, Italy, Spain-1 and Spain-2 (Table 1). The overall
mean APACHE II score was 16.9, with the lowest mean score
(7.9) recorded for patients in Spain-1 and the highest mean
score (19.5) for patients in Spain-2. A total of 357 (58.1%)
patients had an APACHE II score .15, and the mean score
among these patients was 21.6 (median 20.0). SOFA scores
were documented for 108 patients in France and Spain-2.
Mean SOFA scores in these countries were 6.8 and 7.5, respect-
ively. Overall, 60 patients (55.6%) had a SOFA score ≥7, and
the mean score among these patients was 10.1 (median 9.0)
(Table 1). Figure 1 shows the percentage of patients across the
five studies with high disease severity at the time of tigecycline
administration, as evidenced by APACHE II score .15 or SOFA
score ≥7.
Description of cIAI
A description of infection characteristics was available for 590
patients in three studies (Germany, Spain-1 and France)
(Table 2). Diffuse (generalized) peritonitis was the most
common type of cIAI infection, presenting in 51.2% of patients;
32.7% had local peritonitis and 21.6% an intra-abdominal
abscess. The majority of peritonitis cases (65.7%) were classified
as secondary. The most common sites of infection were the
colon/rectum (41.4%), liver/pancreas (21.7%) and small intestine
(19.9%).
Antibiotic treatment
Across the five studies, there were 734 cIAI patients (93.5%) who
received the standard dosage of tigecycline (Table 3). The mean
duration of therapy with tigecycline was 10.6+6.1 days (range
1–78 days). Data on the use of tigecycline as first- or second-line
therapy were available for 781 patients. There was heterogeneity
across the studies in the prescription of tigecycline; however,
overall tigecycline was initiated first-line in 48.7% and second-
line in 51.3% of patients. Tigecycline was used as monotherapy
in 54.8% of cIAI patients and in combination with other antibac-
terials in 45.2% (Table 3). However, there were differences
between the studies, with 81.8% of the patients in Spain-2 re-
ceiving tigecycline in combination with another antibacterial
compared with only 4.3% of the patients in Italy. Data on the
concomitant use of antibacterials were available for 348 patients
in Germany, Spain-1, France and Spain-2 (Table 4). Although
there were differences between countries, the most commonly
used antibiotic classes used in combination with tigecycline
were third- and fourth-generation cephalosporins in Germany
(45.1%), aminoglycosides in France (43.9%) and fluoroquino-
lones in Spain-1 (50.0%) and Spain-2 (33.3%).
Reasons for tigecycline use
Data on the main reasons for tigecycline use in cIAI patients
were available for 785 patients (Table 5). Mainly, tigecycline
was used when resistant pathogens were suspected (42.9%),
when the infection required a broad-spectrum antibiotic or was
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Table 1. Summary of patient characteristics
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Number of cIAI patients 418 162 94 78 33 785
Demographics
male, n (%) 256 (61.2) 89 (54.9) 47 (50.0) 43 (55.1) 22 (66.7) 457 (58.2)
age (years), mean+SD (range) 64.0+12.9
(19–89)
63.9+14.7
(18–92)
59.1+16.5
(18–89)
63.0+14.2
(19–86)
60.6+14.6
(25–84)
63.1+14.0
(18–92)
BMI (kg/m2), mean+SD 27.7+6.9 NA 26.0+5.3 27.3+7.0 NA 27.4+6.7
Clinical characteristics
ICU admission, n (%) 258 (61.7) 75 (46.3) 1 (1.1) 78 (100.0) 32 (100.0) 444 (56.6)
missing/unknown, n 0 0 0 0 1 1
history of prior antibacterial, n (%) 358 (85.6) 127 (78.4) 15 (16.0) 73 (93.6) 31 (93.9) 604 (76.9)
presence of ≥1 comorbidity, n (%) 395 (94.5) 149 (92.0) 73 (80.2) 42 (53.8) 30 (90.9) 689 (88.1)
missing/unknown, n 0 0 3 0 0 3
Mode of infection acquirement
nosocomial, n (%) 281 (67.7) 103 (64.0) 46 (49.5) 52 (66.7) 29 (90.6) 511 (65.6)
community, n (%) 134 (32.3) 58 (36.0) 47 (50.5) 26 (33.3) 3 (9.4) 268 (34.4)
missing/unknown, n 3 1 1 0 1 6
Severity/organ dysfunction scores
APACHE II score, n 386 162 34 NA 32 614
mean+SD (range) 18.5+8.2
(0–59)
14.3+4.3
(4–25)
7.9+4.0
(2–18)
— 19.5+6.0
(6–36)
16.9+7.6
(0–59)
≤15, n (%) 131 (33.9) 84 (51.9) 33 (97.1) — 9 (28.1) 257 (41.9)
≤15, mean (median) 10.5 (12.0) 10.9 (11.0) 7.5 (8.0) — 12.3 (13.0) 10.3 (11.0)
.15, n (%) 255 (66.1) 78 (48.1) 1 (2.9) — 23 (71.9) 357 (58.1)
.15, mean (median) 22.6 (21.0) 17.9 (17.0) 18.0 (18.0) — 22.3 (22.0) 21.6 (20.0)
missing/unknown, n 32 0 60 — 1 93
SOFA score, n NA NA NA 76 32 108
mean+SD (range) — — — 6.8+4.4 (0–17) 7.5+3.6 (0–14) 7.0+4.2 (0–17)
,7, n (%) — — — 36 (47.4) 12 (37.5) 48 (44.4)
,7, mean (median) — — — 2.9 (3.0) 4.0 (5.0) 3.1 (3.0)
≥7, n (%) — — — 40 (52.6) 20 (62.5) 60 (55.6)
≥7 mean (median) — — — 10.4 (10.0) 9.6 (9.0) 10.1 (9.0)
missing/unknown, n — — — 2 1 3
Patients with ≥1 comorbidity, n 395 149 73 42 30 689
comorbid conditionsa
hypertension, n (%) 246 (62.3) NA 31 (42.5) NA 13 (44.8) 290 (58.4)
diabetes mellitus, n (%) 108 (27.3) 67 (45.0) 15 (20.5) 13 (31.0) 6 (20.7) 209 (30.4)
arteriosclerosis/CHD, n (%) 119 (30.1) NA 7 (9.6) NA NA 126 (26.9)
heart failure, n (%) 76 (19.2) 53 (35.6) 4 (5.5) NA 4 (13.8) 137 (21.2)
COPD, n (%) 62 (15.7) 34 (22.8) 8 (11.0) NA 7 (24.1) 111 (17.2)
renal insufficiency, n (%) 131 (33.2) 28 (18.8) 4 (5.5) 4 (9.5) 3 (10.3) 170 (24.7)
hepatic failure, n (%) 39 (9.9) 9 (6.0) 2 (2.7) 0 3 (10.3) 53 (7.7)
neoplasia, n (%) 100 (25.3) 111 (74.5) NA NA 13 (44.8) 224 (39.1)
immunosuppression, n (%) 33 (8.4) 21 (14.1) 8 (11.0) 26 (61.9)b 5 (17.2) 93 (13.5)
obesity, n (%) 107 (27.1) 19 (12.8)c 17 (23.3) 14 (33.3) 0c 157 (22.8)c
alcohol abuse, n (%) 54 (13.7) 7 (4.7) 6 (8.2) NA 2 (6.9) 69 (10.7)
smoking, n (%) 79 (20.0) NA 8 (11.0) NA 1 (3.4) 88 (17.7)
missing/unknown, n 0 0 0 0 1 1
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; NA, not available.
Percentages were calculated for patients with non-missing data only.
aPercentages of comorbid conditions were calculated for patients with at least one comorbidity.
bIncludes neoplasia in France.
cIncludes study-level data from Italy and Spain-2.
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of polymicrobial origin (53.3%) and when previous therapy had
failed (38.6%). Allergy or intolerance to other antibiotics was
the reason given for tigecycline prescription in 14.9% of patients
in Spain-1 and 27.3% in Spain-2. Renal failure was listed as a
reason for 15.4% of patients in France.
Pathogens isolated at baseline
In Germany, Spain-1, France and Spain-2, microbiological data
were available for 623 patients with cIAI. Among these, 464
patients (74.5%) had at least one pathogen and 306 patients
(49.1%) had more than one pathogen isolated from
intra-abdominal specimens at the start of tigecycline therapy.
Among patients with at least one isolate, the most frequently
detected pathogens were E. coli (41.8%), Enterococcus faecium
(40.1%) and Enterococcus faecalis (21.1%). Other notable Gram-
negative pathogens included Enterobacter spp. [55 patients
(11.9%)], Klebsiella pneumoniae [50 patients (10.8%)] and P. aer-
uginosa [45 patients (9.7%)]. Staphylococcus aureus was identi-
fied in 55 (11.9%) patients. A pooled analysis of the proportion
of patients with selected resistant pathogens [including
extended-spectrum b-lactamase (ESBL)-producing E. coli, Kleb-
siella oxytoca and K. pneumoniae, vancomycin-resistant Entero-
coccus (VRE) and methicillin-resistant S. aureus (MRSA)] showed
that, overall, 17.5% of patients had at least one resistant patho-
gen and 2.7% had more than one resistant pathogen at baseline.
Further data on the microbiological findings from these studies
are provided in the accompanying article by Heizmann et al.29
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Figure 1. Disease severity at baseline in patients with cIAI. Percentages
were calculated for patients with non-missing data only. Disease
severity was assessed by APACHE II score in Germany, Italy, Spain-1
and Spain-2, and by SOFA score in France.
Table 2. Description of cIAIs
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Number of patients 418 NA 94 78 NA 590
Infection subtypea
local peritonitis, n (%) 130 (32.3) — 41 (45.6) 9 (15.3) — 180 (32.7)
generalized peritonitis, n (%) 230 (57.2) — 14 (15.6) 38 (64.4) — 282 (51.2)
intra-abdominal abscess, n (%) 72 (17.9) — 35 (38.9) 12 (20.3) — 119 (21.6)
missing/unknown, n 16 — 4 19 — 39
Type of peritonitisb
primary, n (%) 81 (21.1) — 14 (16.3) 0 — 95 (17.5)
secondary, n (%) 285 (74.2) — 48 (55.8) 24 (32.9) — 357 (65.7)
tertiary, n (%) 18 (4.7) — 24 (27.9) 49 (67.1) — 91 (16.8)
missing/unknown, n 34 — 8 5 — 47
Infection sitea
appendix, n (%) 14 (3.8) — 6 (6.4) 1 (1.3) — 21 (3.9)
biliary tract/gall bladder, n (%) 35 (9.6) — 15 (16.0) 8 (10.3) — 58 (10.8)
colon/rectum/large intestine, n (%) 154 (42.1) — 31 (33.0) 38 (48.7) — 223 (41.4)
duodenum/stomach, n (%) 45 (12.3) — 4 (4.3) 6 (7.7) — 55 (10.2)
liver/pancreas, n (%) 81 (22.1) — 25 (26.6) 11 (14.1) — 117 (21.7)
small intestine, n (%) 80 (21.9) — 13 (13.8) 14 (17.9) — 107 (19.9)
other, n (%) 9 (2.5) — 3 (3.2) 12 (15.4) — 24 (4.5)
missing/unknown, n 52 — 0 0 — 52
NA, not available.
Percentages were calculated for patients with non-missing data only.
aPatients could have more than one infection subtype or site.
bRefers to any subtype of infection and includes patients with intra-abdominal abscess who were classified as having secondary or tertiary peritonitis
according to physician reporting.
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Clinical outcome
Clinical response rates for cIAI patients who received the stand-
ard dose of tigecycline are shown in Table 6 and Figures 2–4.
A successful clinical response was documented for 567/733
patients (77.4%) who received tigecycline alone or in combin-
ation, and overall response rates ranged from 61.6% in France
(where all of the patients were in the ICU) to 91.3% in Spain-1
(where only 1.1% were in the ICU) (Figure 2). There was a
trend towards higher response rates in patients with lower
versus higher APACHE II scores (Table 6). Among 330 patients
with an APACHE II score .15 at the time of tigecycline adminis-
tration, there were 250 (75.8%) responders, 54 non-responders
(16.4%) and 26 (7.9%) with an indeterminate outcome.
Among 59 patients in France and Spain-2 with a SOFA score
Table 3. Prescription of tigecycline, alone or in combination, in patients with cIAI
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Number of patients 418 162 94 78 33 785
Standard dosage, n (%) 375 (89.7) 162 (100.0) 93 (98.9) 73 (93.6) 31 (93.9) 734 (93.5)
Duration (days), mean (range)a 10.7 (1–51) 9.5 (3–25) 11.1 (3–25) 9.8 (2–78) 16.0 (6–37) 10.6 (1–78)
Therapy regimen
first-line, n (%) 188 (45.0) 116 (71.6)b 21 (22.3) 43 (58.1) 12 (36.4)b 380 (48.7)b
second-line, n (%) 230 (55.0) 46 (28.4)b 73 (77.7) 31 (41.9) 21 (63.6)b 401 (51.3)b
missing/unknown, n 0 0 0 4 0 4
monotherapy, n (%) 192 (45.9) 155 (95.7) 56 (59.6) 21 (26.9) 6 (18.2) 430 (54.8)
in combination with other antibacterials, n (%) 226 (54.1) 7 (4.3) 38 (40.4) 57 (73.1) 27 (81.8) 355 (45.2)
Percentages were calculated for patients with non-missing data only.
aOnly patients who received a standard dosage regimen of tigecycline were included.
bIncludes study-level data from Italy and Spain-2.
Table 4. Antibacterial agents used in combination with tigecycline for treatment of patients with cIAI
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Number of patients receiving combination therapy 226 7 38 57 27 355a
Agent, n (%)b
third-/fourth-generation cephalosporins 102 (45.1) NA 11 (28.9) 5 (8.8) 3 (11.1) 121 (34.8)
ceftazidime 86 (38.1) NA 11 (28.9) 2 (3.5) 3 (11.1) 102 (29.3)
cefepime 14 (6.2) NA 0 0 0 14 (4.0)
aminoglycosides 4 (1.8) NA 7 (18.4) 25 (43.9) 8 (29.6) 44 (12.6)
amikacin 1 (0.4) NA 6 (15.8) 22 (38.6) 7 (25.9) 36 (10.3)
carbapenems 26 (11.5) NA 4 (10.5) 7 (12.3) 7 (25.9) 44 (12.6)
imipenem 10 (4.4) NA 3 (7.9) 5 (8.8) 2 (7.4) 20 (5.7)
meropenem 14 (6.2) NA 1 (2.6) 1 (1.8) 5 (18.5) 21 (6.0)
fluoroquinolones 36 (15.9) NA 19 (50.0) 3 (5.3) 9 (33.3) 67 (19.3)
ciprofloxacin 28 (12.4) NA 12 (31.6) 3 (5.3) 7 (25.9) 50 (14.4)
glycopeptides 8 (3.5) NA 1 (2.6) 3 (5.3) 3 (11.1) 15 (4.3)
metronidazole 18 (8.0) NA 3 (7.9) 3 (5.3) 4 (14.8) 28 (8.0)
penicillins 24 (10.6) NA 3 (7.9) 14 (24.6) 4 (14.8) 45 (12.9)
piperacillin/tazobactam 7 (3.1) NA 3 (7.9) 12 (21.1) 4 (14.8) 26 (7.5)
NA, not available.
Percentages were calculated for patients with non-missing data only.
aDenominator for percentage calculations in the total column (n¼348) does not include patients in Italy.
bPatients could receive more than one antibacterial in combination with tigecycline.
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≥7, there were 32 (54.2%) responders, 16 non-responders
(27.1%) and 11 (18.6%) with an outcome of indeterminate.
Community-acquired infections were associated with higher
response rates than those acquired in the hospital (81.6%
versus 75.2%, respectively; Figure 3). Seventy-nine of 471
patients (16.8%) with nosocomial infections were classified as
non-responders and 38 (8.1%) had an outcome of indetermin-
ate. The clinical response rate was 80.6% (329/408) for patients
treated with tigecycline as monotherapy and 73.2% (238/325)
for patients who received combination therapy (Figure 4). Forty-
nine of 408 patients (12.0%) treated with monotherapy were
classified as non-responders and 30 (7.4%) had an indetermin-
ate outcome. No difference was observed in clinical response
rates for patients who received tigecycline as first- or second-line
therapy (76.2% versus 76.7%, respectively; Table 6).
Safety profile and patient discontinuation
Data on all-cause AEs, SAEs and reasons for discontinuation were
available for 590 cIAI patients who received tigecycline alone or
in combination in Germany, Spain-1 and France. A total of 499
AEs were documented in 223 patients (37.8%); 151 patients
(25.6%) experienced SAEs. Tigecycline was stopped prematurely
in 162 patients (27.5%); the main reasons recorded were clinical
failure (31.7%) and microbiological failure (18.0%). Data on mor-
tality were available for 785 cIAI patients in all five studies. There
were 147 all-cause patient deaths recorded at any time during
the study, including the follow-up period, giving a mortality
rate of 18.7%. The mortality rate was higher in patients with
higher (.15) versus lower (≤15) APACHE II scores (23.8%
versus 16.0%, respectively), and a similar trend was seen when
Table 5. Reasons for tigecycline use, alone or in combination, in patients with cIAI
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Number of patients 418 162 94 78 33 785
Reason, n (%)a
failure of previous therapyb 226 (54.1) 33 (20.4)c 26 (27.7) 12 (15.4) 6 (18.2)c 303 (38.6)c
suspicion of resistant pathogens 191 (45.7) 102 (63.0)c 14 (14.9) 23 (29.5) 7 (21.2)c 337 (42.9)c
need broad-spectrum coverage/polymicrobial infection 204 (48.8) NA 50 (53.2) 56 (71.8) 22 (66.7)c 332 (53.3)c
allergy to/intolerance of previous antibacterial 6 (1.4) 15 (9.3)c 14 (14.9) 7 (9.0) 9 (27.3)c 51 (6.5)c
renal impairment NA NA NA 12 (15.4) 0c 12 (10.8)c
other NA NA NA 8 (10.3) NA 8 (10.3)
NA, not available.
Percentages were calculated for patients with non-missing data only.
aPatients could have more than one reason.
bPrevious therapy includes all treatments that were given prior to treatment with tigecycline.
cIncludes study-level data from Italy and Spain-2.
Table 6. Clinical response at EOT in patients with cIAI who received the standard dose of tigecycline alone or in combination
Country where study was performed
TotalGermany Italy Spain-1 France Spain-2
Clinical response by disease severity
number of patients 345 162 34 NA 30 571
APACHE II ≤15, n/n (%) 93/116 (80.2) 69/84 (82.1) 28/33 (84.8) — 5/8 (62.5) 195/241 (80.9)
APACHE II .15, n/n (%) 171/229 (74.7) 63/78 (80.8) 0/1 — 16/22 (72.7) 250/330 (75.8)
number of patients NA NA NA 71 30 101
SOFA ,7, n/n (%) — — — 25/32 (78.1) 8/10 (80.0) 33/42 (78.6)
SOFA ≥7, n/n (%) — — — 19/39 (48.7) 13/20 (65.0) 32/59 (54.2)
Clinical response by therapy regimen
number of patients 375 NA 92 69 NA 536
first-line therapy, n/n (%) 130/168 (77.4) — 19/20 (95.0) 24/39 (61.5) — 173/227 (76.2)
second-line therapy, n/n (%) 155/207 (74.9) — 65/72 (90.3) 17/30 (56.7) — 237/309 (76.7)
NA, not available.
Percentages were calculated for patients with non-missing data only. Response was defined as clinical cure or improvement without additional
antibiotic.
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patients were stratified by SOFA score (SOFA ≥7, 28.3%; SOFA
,7, 14.6%). Further data on the safety and tolerability profile
of tigecycline in these observational studies is provided in the ac-
companying article by Guirao et al.30
Discussion
The treatment of cIAIs consists in general of surgical and/or
interventional source control, intensive care and administration
of antibiotics.5,6 The increasing number of infections due to
resistant bacteria (e.g. ESBL producers, VRE, MRSA and
carbapenem-resistant bacteria) calls for new drugs that encom-
pass this spectrum of bacteria. Tigecycline has been investigated
in RCTs and is licensed for treatment of cIAI.12 However, the
mean APACHE II score in these RCTs was 6.1—thus not repre-
senting the severity of illness in (heavily pretreated) patients
with infections due to resistant bacteria, who might benefit
from treatment with tigecycline.
In this analysis, we investigated the real-life clinical use of
tigecycline for the treatment of hospitalized patients with cIAI
in five studies from four European countries. All the studies
were observational and non-interventional in nature, thus docu-
menting the efficacy and safety of tigecycline as it is used in
routine clinical practice. In particular, we were interested in the
type, severity and microbiology of patients’ infections, their con-
comitant treatment with other antibiotics, the specific reasons
for tigecycline administration and the clinical outcome and
safety of tigecycline.
cIAI was the main indication in these studies, accounting for
44.1% of all patients treated with tigecycline in the five studies
across Europe. Prescription of tigecycline was therefore used for
an approved indication and in accordance with the product char-
actersitics.7 In this analysis, tigecycline when administered as
monotherapy or in combination with other antibacterials has
shown efficacy in cIAI patients with mild to moderate severity
(Spain-1) and in high-risk and severely ill patients (Germany,
Italy, France and Spain-2). Patients were severely ill from both
a systemic point of view (presence of comorbid conditions and
high APACHE II or SOFA scores) and a local point of view (high
frequency of generalized peritonitis and infections in the colon/
rectum and low frequency of appendicitis). The characteristics
of patients in these observational studies are quite different
from those enrolled in the registration trials, which excluded
patients with a high disease severity.12 – 15
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Figure 2. Clinical outcome at EOT in patients with cIAI who received the
standard dose of tigecycline alone or in combination. Percentages were
calculated for patients with non-missing data only. Response was
defined as clinical cure or improvement without additional antibiotic.
Non-response was defined as failure or improvement with additional
antibiotic. Patients whose response could not be ascertained were
assigned an indeterminate outcome.
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Figure 3. Clinical response by mode of infection acquirement in patients
with cIAI who received the standard dose of tigecycline alone or in
combination. Percentages were calculated for patients with non-missing
data only. Response was defined as clinical cure or improvement without
additional antibiotic.
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Figure 4. Clinical response in patients with cIAI who received the
standard dose of tigecycline alone or in combination. Percentages were
calculated for patients with non-missing data only. Response was
defined as clinical cure or improvement without additional antibiotic.
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Clinicians saw the indication for tigecycline primarily in
patients with locally advanced and systemically severe cIAI.
The results of the observational trials support the benefit of tige-
cycline in terms of clinical success. The most recent (2010)
guidelines of the Surgical Infection Society and the Infectious
Diseases Society of America (SIS-IDSA) for the management of
cIAI recommend the use of tigecycline only in patients with
mild to moderate disease, based on the limited data available
at the time of publishing and due to the fact that the IDSA
recommends antibacterial coverage of Pseudomonas spp. in
community-acquired cIAI in high-risk or severely ill patients.5 A
European expert group has chosen an approach where tigecyc-
line is advocated for use in post-operative and tertiary periton-
itis—i.e. forms of peritonitis where the likelihood of resistant
bacteria as causative pathogens is much higher than in
community-acquired IAIs of mild to moderate severity.6,31
The new guidelines recently published by the World Society of
Emergency Surgery (WSES) recommend tigecycline for the treat-
ment of hospital-acquired IAIs in both stable non-critical
patients and critically ill patients presenting with risk factors for
multidrug-resistant pathogens.32
It is worth noting that tigecycline is the only drug approved for
treatment of cIAI due to resistant Gram-positive bacteria (MRSA
and VRE).7 The newer antibiotics (daptomycin and linezolid) are
not approved for this indication.33,34 Studies on the treatment
of infections caused by ESBL-producing bacteria have shown
that through an individualized strategy of prescribing with a har-
monized use of different antibiotic classes, the percentage of re-
sistant Gram-negative bacilli decreased significantly.35,36
Therefore, the antibiotic-selective pressure on carbapenems
may be reduced by using other classes for the treatment of
infections caused by ESBL producers (a ‘carbapenem-sparing
strategy’). On the other hand, most of the studies included
patients with pulmonary infections; therefore the results
cannot be extrapolated to patients with cIAI.
As expected, the main reasons for use of tigecycline in
patients with cIAI were its broad-spectrum coverage, failure of
previous antibacterial therapy and suspicion of resistant patho-
gens. This clinical practice is consistent with current international
guidelines recommending tigecycline as single-agent therapy for
the empirical treatment of cIAI.5 There was wide heterogeneity
in clinical practice across the four countries, with 95.7% of cIAI
patients in Italy receiving tigecycline as monotherapy compared
with 18.2% in Spain-2. The high use of combination therapy in
Spain-2 may relate to the high severity of illness and proportion
of nosocomial infections (.90%) among the patients treated
with tigecycline in this study. When used in combination, tigecyc-
line was often paired with third- or fourth-generation cephalos-
porins. This may indicate that the clinicians intended to cover
Pseudomonas spp. The pathogenetic role of Pseudomonas in
cIAI still needs to be clarified, but in the four studies where
patients were investigated microbiologically, the proportion of
isolated P. aeruginosa was in the range of 0%–21%, showing a
large variability across the studies.29 Considering the high selec-
tion of critically ill patients in these studies, coverage of non-
fermenting Gram-negative pathogens, including Pseudomonas,
appears to be necessary in some institutions.37
Despite the fact that many of the patients in these five
studies were critically ill and requiring ICU care at the time of
tigecycline administration, and had clinical factors known to be
associated with failure of treatment for cIAIs (including high
APACHE II scores, advanced age, comorbidity involving organ
dysfunction, peritoneal involvement or diffuse peritonitis and
healthcare-related infection),32 the overall clinical outcomes
were good, and largely in the range of previously reported
results with tigecycline in Phase III trials with populations
showing substantially lower mean APACHE II scores.12 A success-
ful clinical response was observed in 77.4% of all cIAI patients
pooled across the five European studies compared with 80% in
the pooled tigecycline patients of the two pivotal cIAI trials, in
which the mean APACHE II score of tigecycline-treated patients
was 6.3 versus 16.9 in the present analysis.12 In the present ana-
lysis, clinical response rates in cIAI patients receiving tigecycline
ranged from approximately 62% and 68% in France and Spain-2
to 91% in Spain-1. The difference in response rates may reflect
the heterogeneity in patient populations treated with tigecycline
across the studies and the finding that all (100.0%) patients in
the studies from France and Spain-2 were critically ill in the
ICU, compared with only 1.1% of patients in Spain-1. These find-
ings are also consistent with the trend towards lower response
rates observed in patients with higher disease severity, as evi-
denced by clinical response rates stratified by APACHE II and
SOFA scores. The numerically higher clinical response rates
observed in patients who received tigecycline as monotherapy
compared with those who received combination regimens may
be a bias related to the preferred use of combination regimens
in patients with poor risk profiles and higher disease severity.
Consistent with this finding is that the highest percentage of
combination therapy use was observed in the studies from
France and Spain-2, in which all of the patients were in the ICU.
Recent warnings from both the FDA and EMA have highlighted
the numerically higher mortality rate observed in all randomized
trials comparing tigecycline and comparators.16,38 In all Phase III
and IV (cSSTI and cIAI) studies, death occurred in 2.4% (54/
2216) of patients receiving tigecycline and in 1.7% (37/2206)
of patients receiving comparator drugs.7 Taking into account
those findings, the EMA Committee for Medicinal Products
for Human Use (CHMP) recommended changes to the product
information to ensure that it is used appropriately, by making
prescribers aware that the medicine has been associated with
an increased mortality in clinical studies.21
In accordance with previous literature, our analysis showed
that severity of illness, as defined by APACHE II or SOFA score
at baseline, was a predictor of mortality in the group of patients
for whom these data were collected.39,40 Additionally, assuming
that the probability of the occurrence of a fatal outcome is
around 26.2% for a cIAI patient having a disease severity score
close to the mean values found in our observational studies
(estimated APACHE II score of 17),41 the observed actual all-
cause hospital mortality rate (18.7%) was lower than expected
in this group of tigecycline-treated patients.
This analysis has several limitations, and the results should
be viewed as descriptive due to the observational, non-
interventional and non-comparative design of each study. By
definition, observational studies are not allowed to include
randomization and control groups. This is one of the limitations
of the mentioned studies and does not allow comparison of
treatment results with those of another regimen. The data can
be complex to interpret, particularly given the heterogeneity
across the countries in terms of sites, hospitals and patient
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care. Two studies included primarily critically ill patients in the
ICU, whereas three studies also included patients from surgical
wards with a broader range of disease severity scores. The
modality of treatment with tigecycline also varied across
studies, as shown by the variation in use of tigecycline as mono-
therapy or in combination with other antibiotics. Another source
of heterogeneity is the epidemiology of multidrug-resistant
pathogens that varies across Europe, leading to differences in
the clinical approach to empirical treatment. Nevertheless, the
clinical success rates in this observational analysis were similar
across the different countries, healthcare systems, local micro-
biological environments, treatment modalities and prescription
behaviours, indicating a robust clinical value of tigecycline in
real-life scenarios.
In summary, these real-life observational studies in Europe
included a high proportion of seriously ill patients who were
not captured in the Phase III registration trials of tigecycline.
In these patients tigecycline, alone and in combination, achieved
favourable clinical response rates. We believe that this analysis
adds important information to guide the antibacterial manage-
ment of this group of patients, who have a substantial morbidity
and mortality.
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